With SABR 40-45 GY in 5 FX in medical inoperable, not suitable for concurrent chemo/RT stage III NSCLC, 46% OS and 26% PFS at 5-year is comparable to PACIFIC study (43% and 33% respectively). Surprisingly, no >=Grade 3 complications. SABR GTV, no CTV, PTV 5 mm is the key?

This #WorldCancerResearchDay🔬, we extend our gratitude to the researchers, clinicians, and advocates whose dedication drives progress against #lungcancer. Your work brings hope to patients worldwide. #CancerResearch #GlobalHealth

🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine ASTRO

🚫 In >2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms). 🔹 PC-specific survival 98% 🔹 Slight ↓ in biochemical failure with WPRT 🔹 More grade 2 GI adverse events ⁉️how to reconcile

We’ve kicked off at #ASTRO25 ☢️! Our team at RadioSerra Radiation Therapy is in SanFran 🌁 to get the utmost updates and caring for our patients. Something VERY 🐻 new this year: we are not talking only about cancer related treatments! #RadOnc #California

SWIPE it 📲 When in #Houston 🤠 at MD Anderson Cancer Center , me and Ibrahim were roommates beginning our journey and careers around the #oncology ☢️ world. Almost 15y later; here we are at American Society for Radiation Oncology (ASTRO) in SanFran 🌉 . Great seeing you buddy. #ASTRO25

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

Our team at RadioSerra Radiation Therapy brought 2 abstracts 🫁 to #ASTRO25 ASTRO in San Francisco 🇺🇸 this year. Great effort everyone. Pleasure to work with all of you. #RadioSerra

Smoking is bad. We know. 🫁 Lung cancer is directly related to it (mostly). But, reassuring that: smoking CLEARLY ruins your lung cancer treatment outcomes. 🚬 Our study brings to #ASTRO25 more evidence that cessation is necessary. Just stop. 🛑 #RadioSerra

Always good to have 🙌🏾 fun and learn new tech ☢️ with Accuray ; thanks again 🔥 #ASTRO2025

🫁⚡ SABR in ILD — can planning make it safer? ASPIRE-ILD (secondary dosimetric analysis) in early-stage NSCLC + ILD (n=39) treated 50 Gy/5 fx (QOD) 🧩 Trial essentials • Design: single-arm SABR; dosimetry ↔ outcomes • Regimen: 50 Gy / 5 fx, every other day 🎯 What predicted

I has become a tradition! “Autograph-like” picture w/ this 🤳 amazing friend and superstar Shankar Siva 🇦🇺; CONGRATS 🍾 on this amazing project - thanks for 🍺 and see you soon! 🔜 ✈️ #IROCK #ASTRO25 #PETERMAC

That’s a wrap for 2025’s ASTRO #ASTRO25; see you in Boston 🦞 #ASTRO26 #RadioSerra

Is #AI 🤖 the future of ☢️ #RadOnc? #ASTRO25 pooled us: What innovation will most transform radiation oncology in the next 10 years? Cast your vote by dropping a ball; (Options in comments) Guess what??? #RadOnc #RadioSerra

🧠 You can shrink the tumour—but not the tumour bed. New RAPIDO analysis in BJS 2025 shows why small margins after TNT can turn dangerous 👇 💡 Trial: RAPIDO (n = 920, LARC) 🎯 TNT = 5×5 Gy + 6 CAPOX / 9 FOLFOX → TME vs CRT = 25–28×1.8–2 Gy + capecitabine → TME 📊 8-year

We are proceeding with a similar approach to guide SABR versus surgery in early-stage lung ca, consolidative RT in stage IV ca. Cumulative , non-linear nature of interactions among risk factors are beyond the capacity of our brain. AI is the future in guiding personalized TX.

We’ve kicked off the #2026 season! #ASCOGU26 Congrats to our team; special efforts by Nicole Arbex #RadioSerra

One of the greatest times of the year: the annual GBOT Alerta meeting. 🫁 🫁 🫁 See y’all in 2026 #GBOT #GBOT25

Thanks for including me in this project Cinthya Sternberg 📕; honored to be part of it. 🫁 #GBOT

Back to what I think is a wrap up for the season: 🌎 thanks AstraZeneca for keeping our MDTs always on the run. 🫁 #RadioSerra